142 related articles for article (PubMed ID: 38460249)
1. Circulating tumor DNA for predicting recurrence in patients with operable breast cancer: a systematic review and meta-analysis.
Nader-Marta G; Monteforte M; Agostinetto E; Cinquini M; Martins-Branco D; Langouo M; Llombart-Cusac A; Cortés J; Ignatiadis M; Torri V; Apolone G; Cappelletti V; Pruneri G; de Azambuja E; Di Cosimo S
ESMO Open; 2024 Mar; 9(3):102390. PubMed ID: 38460249
[TBL] [Abstract][Full Text] [Related]
2. Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.
Cullinane C; Fleming C; O'Leary DP; Hassan F; Kelly L; O'Sullivan MJ; Corrigan MA; Redmond HP
JAMA Netw Open; 2020 Nov; 3(11):e2026921. PubMed ID: 33211112
[TBL] [Abstract][Full Text] [Related]
3. Association of Circulating Tumor DNA and Circulating Tumor Cells After Neoadjuvant Chemotherapy With Disease Recurrence in Patients With Triple-Negative Breast Cancer: Preplanned Secondary Analysis of the BRE12-158 Randomized Clinical Trial.
Radovich M; Jiang G; Hancock BA; Chitambar C; Nanda R; Falkson C; Lynce FC; Gallagher C; Isaacs C; Blaya M; Paplomata E; Walling R; Daily K; Mahtani R; Thompson MA; Graham R; Cooper ME; Pavlick DC; Albacker LA; Gregg J; Solzak JP; Chen YH; Bales CL; Cantor E; Shen F; Storniolo AMV; Badve S; Ballinger TJ; Chang CL; Zhong Y; Savran C; Miller KD; Schneider BP
JAMA Oncol; 2020 Sep; 6(9):1410-1415. PubMed ID: 32644110
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of ctDNA detection in patients with early breast cancer undergoing neoadjuvant therapy: A systematic review and meta-analysis.
Papakonstantinou A; Gonzalez NS; Pimentel I; Suñol A; Zamora E; Ortiz C; Espinosa-Bravo M; Peg V; Vivancos A; Saura C; Villacampa G; Oliveira M
Cancer Treat Rev; 2022 Mar; 104():102362. PubMed ID: 35219090
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer.
Garcia-Murillas I; Chopra N; Comino-Méndez I; Beaney M; Tovey H; Cutts RJ; Swift C; Kriplani D; Afentakis M; Hrebien S; Walsh-Crestani G; Barry P; Johnston SRD; Ring A; Bliss J; Russell S; Evans A; Skene A; Wheatley D; Dowsett M; Smith IE; Turner NC
JAMA Oncol; 2019 Oct; 5(10):1473-1478. PubMed ID: 31369045
[TBL] [Abstract][Full Text] [Related]
6. Perioperative circulating tumor DNA as a potential prognostic marker for operable stage I to IIIA non-small cell lung cancer.
Li N; Wang BX; Li J; Shao Y; Li MT; Li JJ; Kuang PP; Liu Z; Sun TY; Wu HQ; Ou W; Wang SY
Cancer; 2022 Feb; 128(4):708-718. PubMed ID: 35076939
[TBL] [Abstract][Full Text] [Related]
7. Circulating tumor DNA as a Predictive and Prognostic Biomarker in the Perioperative Treatment of Muscle-invasive Bladder Cancer: A Systematic Review.
Crupi E; de Padua TC; Marandino L; Raggi D; Dyrskjøt L; Spiess PE; Sonpavde GP; Kamat AM; Necchi A
Eur Urol Oncol; 2024 Feb; 7(1):44-52. PubMed ID: 37330413
[TBL] [Abstract][Full Text] [Related]
8. Circulating Tumor DNA Dynamics as Prognostic Markers in Locally Advanced and Metastatic Esophageal Squamous Cell Carcinoma.
Ng HY; Ko JMY; Lam KO; Kwong DLW; Lo AWI; Wong IYH; Wong CLY; Chan SY; Chan KK; Law TT; Dai W; Fong HCH; Choy FSF; Lo CK; Chen C; Law SYK; Lung ML
JAMA Surg; 2023 Nov; 158(11):1141-1150. PubMed ID: 37728901
[TBL] [Abstract][Full Text] [Related]
9. Circulating Tumor DNA as a Minimal Residual Disease Assessment and Recurrence Risk in Patients Undergoing Curative-Intent Resection with or without Adjuvant Chemotherapy in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Chidharla A; Rapoport E; Agarwal K; Madala S; Linares B; Sun W; Chakrabarti S; Kasi A
Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373376
[TBL] [Abstract][Full Text] [Related]
10. Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse.
Cailleux F; Agostinetto E; Lambertini M; Rothé F; Wu HT; Balcioglu M; Kalashnikova E; Vincent D; Viglietti G; Gombos A; Papagiannis A; Veys I; Awada A; Sethi H; Aleshin A; Larsimont D; Sotiriou C; Venet D; Ignatiadis M
JCO Precis Oncol; 2022 Sep; 6():e2200148. PubMed ID: 36170624
[TBL] [Abstract][Full Text] [Related]
11. Prognostic Value of ctDNA Detection in Patients With Locally Advanced Rectal Cancer Undergoing Neoadjuvant Chemoradiotherapy: A Systematic Review and Meta-analysis.
Chang L; Zhang X; He L; Ma Q; Fang T; Jiang C; Ma Z; Li Q; Wu C; Tao J
Oncologist; 2023 Dec; 28(12):e1198-e1208. PubMed ID: 37294663
[TBL] [Abstract][Full Text] [Related]
12. Association of preoperative and postoperative circulating tumour DNA (ctDNA) with PIK3CA gene mutation with risk of recurrence in patients with non-metastatic breast cancer.
Hassan F; Wang JH; O'Leary DP; Corrigan M; Redmond HP
Surg Oncol; 2024 Jun; 54():102060. PubMed ID: 38603927
[TBL] [Abstract][Full Text] [Related]
13. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.
Tan L; Sandhu S; Lee RJ; Li J; Callahan J; Ftouni S; Dhomen N; Middlehurst P; Wallace A; Raleigh J; Hatzimihalis A; Henderson MA; Shackleton M; Haydon A; Mar V; Gyorki DE; Oudit D; Dawson MA; Hicks RJ; Lorigan P; McArthur GA; Marais R; Wong SQ; Dawson SJ
Ann Oncol; 2019 May; 30(5):804-814. PubMed ID: 30838379
[TBL] [Abstract][Full Text] [Related]
14. Circulating tumor DNA as a prognostic marker in high-risk endometrial cancer.
Feng W; Jia N; Jiao H; Chen J; Chen Y; Zhang Y; Zhu M; Zhu C; Shen L; Long W
J Transl Med; 2021 Feb; 19(1):51. PubMed ID: 33536036
[TBL] [Abstract][Full Text] [Related]
15. Impact of Body Mass Index on Presence of ctDNA and Disease Recurrence after Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: Analysis from BRE12-158.
Ballinger TJ; Jiang G; Kassem N; Radovich M; Schneider BP
Clin Cancer Res; 2021 Feb; 27(4):1195-1199. PubMed ID: 33199491
[TBL] [Abstract][Full Text] [Related]
16. Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
Alqahtani A; Alloghbi A; Coffin P; Yin C; Mukherji R; Weinberg BA
Surg Oncol; 2023 Dec; 51():102007. PubMed ID: 37852124
[TBL] [Abstract][Full Text] [Related]
17. Circulating DNA in the neoadjuvant setting of early stage colon cancer.
Bregni G; Pretta A; Senti C; Acedo Reina E; Vandeputte C; Trevisi E; Gkolfakis P; Kehagias P; Deleporte A; Van Laethem JL; Vergauwe P; Van den Eynde M; Deboever G; Janssens J; Demolin G; Holbrechts S; Clausse M; De Grez T; Peeters M; D'Hondt L; Geboes K; Besse-Hammer T; Rothé F; Flamen P; Hendlisz A; Sclafani F
Acta Oncol; 2022 Oct; 61(10):1223-1229. PubMed ID: 35866544
[TBL] [Abstract][Full Text] [Related]
18. Association of ctDNA detection and recurrence assessment in patients with neoadjuvant treatment.
Zhou J; Mo H; Hu D; Zhao X; Zhou H; Pan J
Cancer Med; 2023 Oct; 12(19):19794-19806. PubMed ID: 37746916
[TBL] [Abstract][Full Text] [Related]
19. Targeted next-generation sequencing of circulating-tumor DNA for tracking minimal residual disease in localized colon cancer.
Tarazona N; Gimeno-Valiente F; Gambardella V; Zuñiga S; Rentero-Garrido P; Huerta M; Roselló S; Martinez-Ciarpaglini C; Carbonell-Asins JA; Carrasco F; Ferrer-Martínez A; Bruixola G; Fleitas T; Martín J; Tébar-Martínez R; Moro D; Castillo J; Espí A; Roda D; Cervantes A
Ann Oncol; 2019 Nov; 30(11):1804-1812. PubMed ID: 31562764
[TBL] [Abstract][Full Text] [Related]
20. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
Szabados B; Kockx M; Assaf ZJ; van Dam PJ; Rodriguez-Vida A; Duran I; Crabb SJ; Van Der Heijden MS; Pous AF; Gravis G; Herranz UA; Protheroe A; Ravaud A; Maillet D; Mendez MJ; Suarez C; Linch M; Prendergast A; Tyson C; Stanoeva D; Daelemans S; Rombouts M; Mariathasan S; Tea JS; Mousa K; Sharma S; Aleshin A; Banchereau R; Castellano D; Powles T
Eur Urol; 2022 Aug; 82(2):212-222. PubMed ID: 35577646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
